Arcellx CFO Sells 72,048 Shares for $115 Each, Gains CVRs in Gilead Merger

*TL;DR – Arcellx CFO Michelle Gilson sold 72,048 shares at $115 each, receiving cash and a contingent value right (CVR) worth up to $5 per share as part of the Gilead Sciences merger.*

Context Arcellx (ACLX) is being acquired by Gilead Sciences, creating a wholly owned subsidiary structure. The merger agreement provides cash and CVRs to shareholders who tender their shares before the offer expires. A CVR is a contract that pays an additional amount if certain post‑merger conditions are met.

Key Facts - Gilson tendered 67,048 personally held shares and 5,000 shares owned by a family charitable foundation. Each share fetched $115 in cash plus one CVR, potentially adding $5 per share. - All outstanding stock options with exercise prices of $56.15, $31.03, $19.97 and $8.66 were cancelled. Holders received cash equal to the excess of $115 over each exercise price and one CVR per option‑share. - Every restricted stock unit (RSU), whether vested or not, was also cancelled. Holders got cash equal to $115 per RSU and one CVR per unit. - The filing records a grant of 59,028 performance‑based RSUs, each granting the right to one Arcellx share under the merger terms. Those units were simultaneously cancelled and converted into cash and CVRs.

What It Means The transaction converts all of Gilson’s equity exposure into liquid cash and conditional future payments, aligning her compensation with the merger outcome. The CVR component ties additional value to Gilead’s post‑merger performance, a common feature in biotech consolidations. For investors, the CFO’s disposal signals confidence in the cash component and acceptance of the merger’s risk profile.

Looking Ahead Watch for the CVR settlement timeline and any performance milestones that could trigger the $5 per share payout, as they will affect the final value realized by insiders and shareholders alike.